Jazz Pharmaceuticals plc (JAZZ)
The company now
Jazz Pharmaceuticals plc is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Dublin. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $4.3 billion and a loss of $356 million (its filed statements).
From its filings and filed figures; the desk's account of it is not written yet.
Where the revenue comes from
fiscal 2025, as filedRevenue by product, fiscal 2025
| Product | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| Xywav | $1.66B | $1.47B | 38.8% |
| Epidiolex Epidyolex | $1.06B | $972M | 24.8% |
| Rylaze Enrylaze | $403M | $411M | 9.4% |
| Zepzelca | $307M | $320M | 7.2% |
| High Sodium AG Oxybate Product Royalty Revenue | $212M | $218M | 5.0% |
| Defitelio Defibrotide | $199M | $217M | 4.7% |
| Vyxeos | $147M | $163M | 3.4% |
| Xyrem | $146M | $234M | 3.4% |
| Modeyso | $48.0M | n/a | 1.1% |
| Other Royalties and Contract Revenue | $34.0M | $30.2M | 0.8% |
| Ziihera | $24.8M | $1.1M | 0.6% |
| Sativex | $16.3M | $18.9M | under 1% |
| Other Products | $14.2M | $11.5M | under 1% |
Revenue by region, fiscal 2025
| Region | Fiscal 2025 | Fiscal 2024 | Share of revenue |
|---|---|---|---|
| United States | $3.83B | $3.66B | 89.8% |
| Europe | $341M | $313M | 8.0% |
| Other | $94.9M | $96.1M | 2.2% |
As tagged in its annual report (Form 10-K, filed Feb 24, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.
The desk's written account of this company, its Past, Present and Future, is not on file yet.
How the company works
The desk has not read this company's annual report yet.
The record in brief
The desk has not written this company's report yet.